Molecular Response Assessment From Circulating Tumor DNA in Patients With Ovarian Cancer Treated With the WEE1 Inhibitor Azenosertib Transcriptomic data from 160 patients in the phase III Eastern ...
The ArteraAI Prostate Test is now available to predict mortality risk and guide treatment for metastatic hormone-sensitive prostate cancer. The ArteraAI Prostate Test was launched to provide a digital ...
Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ) ...
WASHINGTON -- Darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) significantly improved outcomes compared with ADT alone in men with metastatic hormone-sensitive prostate cancer (mHSPC), ...
Adding darolutamide to standard treatment for aggressive prostate cancer reduced the risk of the disease spreading in an ...
The Decipher genomic test could help doctors decide which high-risk prostate cancer patients need abiraterone hormone therapy ...
Adding radiation therapy or surgery to the primary tumor does not improve progression-free survival in men already receiving best systemic therapy for de novo metastatic prostate cancer, a phase 2 ...
In "Beyond Diagnosis: Metastatic Castration-Sensitive Prostate Cancer," Cleveland Clinic oncologist Christopher Wee, MD, and host John Mangels discuss how clinicians can guide patients through the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results